ACADIA Pharmaceuticals Inc Corporate Call Announces Top-line Results from Phase 3 ENHANCE Trial Transcript
Good day, ladies and gentlemen, and welcome to ACADIA Pharmaceuticals conference call. My name is Carmen, and I'll be your coordinator for today. (Operator Instructions) I would now like to turn the presentation over to Mark Johnson, Vice President of Investor Relations at ACADIA. Please proceed.
Thank you, Carmen. Good afternoon and thank you for joining us on today's call to discuss the top line results from the Phase III ENHANCE study evaluating pimavanserin as an adjunctive schizophrenic treatment for adult patients with inadequate response to their existing antipsychotic therapy.
On today's call Steve Davis, our Chief Executive Officer, will provide opening remarks. Following Steve, Dr. Serge Stankovic, our President, will discuss the Phase III ENHANCE results in greater details. Following Steve's closing remarks, we'll conduct a Q&A session. Michael Yang, our Chief Commercial Officer; and Elena Ridloff, our Chief Financial Officer, will also be available for Q&A. I would also like to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
